InsiderPulse
← 10-K / 10-Q
10-QORMP

ORAMED PHARMACEUTICALS INC.

Filed 2026-05-19Period ending 2026-03-31
EDGAR ↗All periods →

Income Statement

Line Item2026-03-31Q/QY/Y
Revenue$2.0M+0.0%
Cost of Revenue$2.0M+0.0%
Gross Profit$13K+0.0%
R&D Expense$1.6M-27.7%
SG&A Expense$2.1M-10.5%
Operating Income-$3.7M+18.7%
Pre-tax Income$49.4M+800.5%
Income Tax$11.1M+1805.8%
Net Income$38.3M+601.3%
EPS (Basic)$0.94+594.7%
EPS (Diluted)$0.91+578.9%

Balance Sheet

Line Item2026-03-31Q/QY/Y
Cash & Equivalents$13.2M-71.3%
Short-term Investments$5.0M-8.3%+34.4%
Current Assets$68.2M-48.9%-48.2%
Total Assets$268.8M+16.5%+82.2%
Current Liabilities$10.6M-44.7%+92.3%
Stockholders' Equity$238.3M+19.3%+69.2%

Cash Flow

Line Item2026-03-31Q/QY/Y
Operating Cash Flow-$2.9M+17.2%
Capital Expenditures$5K+66.7%
Investing Cash Flow-$19.5M-182.5%
Financing Cash Flow-$10.4M
Free Cash Flow-$2.9M+17.1%